3 assets in Malignant Soft Tissue Neoplasm

Therapeutic assets addressing Malignant Soft Tissue Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Malignant Soft Tissue Neoplasm	National Cancer Institute (NCI)	P3	B (60)
Nivolumab Malignant Soft Tissue Neoplasm	National Cancer Institute (NCI)	P3	B (60)
Ipilimumab Malignant Soft Tissue Neoplasm	National Cancer Institute (NCI)	P3	B (59)